A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Genmab
Qilu Pharmaceutical Co., Ltd.
AstraZeneca
AstraZeneca
Eli Lilly and Company
Eli Lilly and Company
Inspirna, Inc.
Sun Yat-sen University
Oncology Institute of Southern Switzerland
Sanofi